Severin Guetter

Severin Guetter

Auto-generated profile, based on publicly available information

Severin Guetter

Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
MWMelanie Werner-Klein
Melanie Werner-Klein
AGAna Grujovic
Ana Grujovic
CIChristoph Irlbeck
Christoph Irlbeck
MOMilan Obradović
Milan Obradović
MHMartin Hoffmann
Martin Hoffmann
CKChristoph A. Klein
Christoph A. Klein
Although thousands of breast cancer cells disseminate and home to bone marrow until primary surgery, usually less than a handful will succeed in establishing manifest metastases months to years later. To identify signals that support survival or outgrowth in patients, we profile rare bone marrow-derived disseminated cancer cells (DCCs) long before manifestation of metastasis and identify IL6/PI3K-signaling as candidate pathway for DCC activation. Surprisingly, and similar to mammary epithelial cells, DCCs lack membranous IL6 receptor expression and mechanistic dissection reveals IL6 trans-signaling to regulate a stem-like state of mammary epithelial cells via gp130. Responsiveness to IL6 trans-signals is found to be niche-dependent as bone marrow stromal and endosteal cells down-regulate gp130 in premalignant mammary epithelial cells as opposed to vascular niche cells.PIK3CAactivation renders cells independent from IL6 trans-signaling. Consistent with a bottleneck function of microenvironmental DCC control, we findPIK3CAmutations highly associated with late-stage metastatic cells while being extremely rare in early DCCs. Our data suggest that the initial steps of metastasis formation are often not cancer cell-autonomous, but also depend on microenvironmental signals.

16 May 2025 in Nature Cancer
Verified
Journal Article
Open access
PDF file
SGSeverin Guetter
Severin Guetter
CKCourtney König
Courtney König
HKHuiqin Koerkel-Qu
Huiqin Koerkel-Qu
AMAleksandra Markiewicz
Aleksandra Markiewicz
SSSebastian Scheitler
Sebastian Scheitler
MWMelanie Werner-Klein
Melanie Werner-Klein
To investigate the early, poorly understood events driving metastatic progression, we searched for the earliest detectable disseminated cancer cells (DCCs), also often referred to as disseminated tumor cells (DTCs), in sentinel lymph node (SLN) biopsies of 492 patients with stage I–III melanoma. Using micromanipulator-assisted isolation of rare DCCs, single-cell mRNA and DNA sequencing, codetection by indexing immunofluorescence imaging and survival analysis, we identified melanoma-associated chondroitin sulfate proteoglycan (MCSP)+ melanoma cells as metastasis founder cells (MFCs). We found that DCCs entering SLNs predominantly exhibited a transitory phenotype that, upon interferon-γ exposure triggered by CD8 T cells, dedifferentiated into a neural-crest-like phenotype. This was accompanied by increased production of small extracellular vesicles (sEVs) carrying the immunomodulatory proteins CD155 and CD276 but rarely programmed cell death protein 1 ligand 1. The sEVs suppressed CD8 T cell proliferation and function, facilitating colony formation. Targeting MCSP+ MFCs or their immune escape mechanisms could be key to curing melanoma early by preventing manifestation of metastasis.